Ourobionics is a start-up with a simple, but holistic, and innovative vision: to go beyond bioprinting. Ourobionics strives to empower researchers, developers, and manufacturers in various fields, by facilitating their journey from the lab to the market.
Our proprietary bioprinting technology, DomoBIO, is a multi-technology and multi-tool bioprinter with focus on regenerative medicine especially designed to become a multi-purpose technology and contribute to democratize the biofabrication by making accessible medical research.
Allegro 3D is an emerging 3D printing and bioprinting company located in San Diego, a world hub for biotechnology. At the convergence of advanced additive manufacturing, stem cell biology and biomaterials, Allegro 3D’s expertise in bioprinting and biomaterials enables high-throughput manufacturing of advanced biomedical devices, cell matrices and precision human tissues for cell culture, drug screening, therapeutics and regenerative medicine.
Axolotl Biosystems creates high-resolution desktop 3D bioprinters and bioinks capable of producing functional three dimensional living tissues. Built to reduce the high costs of traditional 3D bioprinting systems, the accessibility to researchers and flexible open system architecture for construct design is making Axolotl Biosystems products the platform of choice for leading bioengineering laboratories around the world.
Based in Gothenburg Sweden, Fluicell is a company that has commercialized a product portfolio to study single cells, primarily in the field of drug development. Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail. As a further development of Fluicell's existing product portfolio, the company has developed a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar®. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled.
Advanced Solutions is dedicated to the discovery, design, and development of integrated software and hardware solutions for the fields of science that involve living organisms, molecular biology, and biotechnology.
Headquartered in New York, NY, VIVAX BIO is a global biotech company focusing on 3D bioprinting and working on the whole range of the hardware, materials, technologies, and products constituting this nascent industry. Our product pipeline – from the earliest stages of R&D to commercial manufacturing - comprises items as diverse as our FABION bioprinter, a new line of bioprinters based on different technologies, including in situ portable bioprinters, and various tissue and organ constructs.
Unleash the power of electro-hydrodynamically enhanced bioprinting. The FLUX-1 is an advanced bioprinter that combines conventional bioprinting technologies with the advanced capabilities of electro-hydrodynamic printing (EHDP).
FluidForm has the exclusive license to FRESH technology from Carnegie Mellon University, and is focused on advancing applications of the technology in biofabrication, regenerative medicine and other industries.
Inventia Life Science Pty Ltd (ILS) is an Australian privately-owned company established in Sydney in 2013. ILS has a core focus on the development, manufacture and sale of equipment and reagents for advanced medical research assays by means of 3D bioprinting.
Volumetric, Inc. was founded in 2018 by Jordan Miller and Bagrat Grigoryan. Our mission is to empower the next generation of advanced biofabrication with high quality materials and systems for 3D bioprinting.
Founded in 2014 by a team of leading experts with experience in biofabrication, SunP Biotech International (SunP) is a high-tech research and manufacturing company specialized in 3D bioprinting and tissue engineering.
SE3D.com is an EdTech startup, funded by the National Science Foundation, specializing in science education courseware and desktop 3D bioprinters for K9-14. Our unique curriculum and equipment is designed to prepare and propel the next generation of biomedical scientists, engineers and innovators.
International Stem Cell Corporation (OTCBB:ISCO) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection.
Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world.